Trade Orgenesis Inc. - ORGS CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.06 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Orgenesis Inc ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Prev. Close* | 0.6 |
Open* | 0.6 |
1-Year Change* | -56.52% |
Day's Range* | 0.58 - 0.61 |
52 wk Range | 0.38-2.64 |
Average Volume (10 days) | 306.40K |
Average Volume (3 months) | 1.87M |
Market Cap | 19.24M |
P/E Ratio | -100.00K |
Shares Outstanding | 28.75M |
Revenue | 35.63M |
EPS | -0.52 |
Dividend (Yield %) | N/A |
Beta | 1.02 |
Next Earnings Date | Nov 8, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Sep 29, 2023 | 0.58 | -0.02 | -3.33% | 0.60 | 0.61 | 0.58 |
Sep 28, 2023 | 0.60 | -0.02 | -3.23% | 0.62 | 0.63 | 0.60 |
Sep 27, 2023 | 0.60 | 0.00 | 0.00% | 0.60 | 0.60 | 0.60 |
Sep 26, 2023 | 0.58 | -0.02 | -3.33% | 0.60 | 0.60 | 0.58 |
Sep 25, 2023 | 0.60 | -0.01 | -1.64% | 0.61 | 0.61 | 0.60 |
Sep 22, 2023 | 0.61 | 0.02 | 3.39% | 0.59 | 0.64 | 0.57 |
Sep 21, 2023 | 0.59 | -0.04 | -6.35% | 0.63 | 0.63 | 0.59 |
Sep 20, 2023 | 0.57 | -0.05 | -8.06% | 0.62 | 0.62 | 0.57 |
Sep 19, 2023 | 0.60 | -0.04 | -6.25% | 0.64 | 0.65 | 0.59 |
Sep 18, 2023 | 0.68 | 0.03 | 4.62% | 0.65 | 0.71 | 0.65 |
Sep 15, 2023 | 0.65 | 0.02 | 3.17% | 0.63 | 0.66 | 0.63 |
Sep 14, 2023 | 0.68 | 0.02 | 3.03% | 0.66 | 0.69 | 0.66 |
Sep 13, 2023 | 0.69 | 0.03 | 4.55% | 0.66 | 0.70 | 0.66 |
Sep 12, 2023 | 0.67 | 0.01 | 1.52% | 0.66 | 0.70 | 0.66 |
Sep 11, 2023 | 0.67 | -0.05 | -6.94% | 0.72 | 0.76 | 0.67 |
Sep 8, 2023 | 0.70 | 0.06 | 9.37% | 0.64 | 0.70 | 0.64 |
Sep 7, 2023 | 0.63 | -0.05 | -7.35% | 0.68 | 0.68 | 0.61 |
Sep 6, 2023 | 0.67 | -0.06 | -8.22% | 0.73 | 0.73 | 0.66 |
Sep 5, 2023 | 0.69 | 0.12 | 21.05% | 0.57 | 0.80 | 0.57 |
Sep 1, 2023 | 0.56 | 0.06 | 12.00% | 0.50 | 0.59 | 0.50 |
Orgenesis Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Wednesday, November 8, 2023 | ||
Time (UTC) 10:59 | Country US
| Event Q3 2023 Orgenesis Inc Earnings Release Q3 2023 Orgenesis Inc Earnings ReleaseForecast -Previous - |
Friday, December 15, 2023 | ||
Time (UTC) 15:00 | Country US
| Event Orgenesis Inc Annual Shareholders Meeting Orgenesis Inc Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 36.025 | 35.502 | 7.652 | 3.899 | 1.852 |
Revenue | 36.025 | 35.502 | 7.652 | 3.899 | 1.852 |
Cost of Revenue, Total | 1.633 | 1.221 | |||
Gross Profit | 34.392 | 0.631 | |||
Total Operating Expense | 44.679 | 54.167 | 103.433 | 25.874 | 4.815 |
Selling/General/Admin. Expenses, Total | 31.926 | 14.091 | 15.395 | 10.19 | 1.883 |
Research & Development | 9.169 | 36.347 | 87.056 | 15.453 | 1.635 |
Depreciation / Amortization | 0.961 | 1.864 | 1.182 | 1.064 | 0.203 |
Operating Income | -8.654 | -18.665 | -95.781 | -21.975 | -2.963 |
Interest Income (Expense), Net Non-Operating | -3.477 | -1.789 | -1.308 | -0.956 | -0.035 |
Other, Net | 0.171 | 2.503 | 0.353 | 0.113 | 0.008 |
Net Income Before Taxes | -11.96 | -17.951 | -96.736 | -22.818 | -2.99 |
Net Income After Taxes | -12.169 | -18.059 | -95.127 | -22.589 | -2.907 |
Net Income Before Extra. Items | -14.889 | -18.053 | -95.088 | -22.49 | -2.744 |
Net Income | -14.889 | -18.053 | 1.11 | -24.121 | -2.744 |
Income Available to Common Excl. Extra. Items | -14.889 | -18.053 | -95.088 | -22.49 | -2.744 |
Income Available to Common Incl. Extra. Items | -14.889 | -18.053 | 1.11 | -24.121 | -2.744 |
Diluted Net Income | -14.889 | -18.053 | 1.11 | -24.121 | -2.744 |
Diluted Weighted Average Shares | 25.0963 | 24.2737 | 21.3203 | 15.908 | 15.423 |
Diluted EPS Excluding Extraordinary Items | -0.59328 | -0.74373 | -4.45997 | -1.41375 | -0.17792 |
Diluted Normalized EPS | -0.56763 | -0.69379 | -4.45997 | -1.41375 | -0.17792 |
Unusual Expense (Income) | 0.99 | 1.865 | |||
Other Operating Expenses, Total | 0 | -0.2 | -0.833 | -0.127 | |
Minority Interest | -2.72 | 0.006 | 0.039 | 0.099 | 0.163 |
Dividends per Share - Common Stock Primary Issue | 0 | ||||
Total Extraordinary Items | 0 | 96.198 | -1.631 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 6.975 | 7.044 | 13.624 | 7.988 | 7.201 |
Revenue | 6.975 | 7.044 | 13.624 | 7.988 | 7.201 |
Total Operating Expense | 9.893 | 10.532 | 14.303 | 7.995 | 11.933 |
Selling/General/Admin. Expenses, Total | 3.165 | 3.818 | 10.539 | 6.339 | 7.401 |
Research & Development | 3.606 | 3.448 | 2.064 | 1.07 | 3.88 |
Depreciation / Amortization | 0.361 | 0.342 | 0.239 | 0.24 | 0.241 |
Other Operating Expenses, Total | -0.06 | -0.081 | |||
Operating Income | -2.918 | -3.488 | -0.679 | -0.007 | -4.732 |
Interest Income (Expense), Net Non-Operating | -0.65 | -0.645 | -0.592 | -1.375 | -0.756 |
Other, Net | -0.002 | 0.001 | 0.171 | -0.001 | 0.007 |
Net Income Before Taxes | -3.57 | -4.132 | -1.1 | -1.383 | -5.481 |
Net Income After Taxes | -3.661 | -4.261 | -1.272 | -1.408 | -5.492 |
Minority Interest | -0.466 | 0.072 | -2.825 | 0.052 | 0.065 |
Net Income Before Extra. Items | -4.127 | -4.189 | -4.097 | -1.356 | -5.427 |
Total Extraordinary Items | |||||
Net Income | -4.127 | -4.189 | -4.097 | -1.356 | -5.427 |
Income Available to Common Excl. Extra. Items | -4.127 | -4.189 | -4.097 | -1.356 | -5.427 |
Income Available to Common Incl. Extra. Items | -4.127 | -4.189 | -4.097 | -1.356 | -5.427 |
Diluted Net Income | -4.127 | -4.189 | -4.097 | -1.356 | -5.427 |
Diluted Weighted Average Shares | 28.3578 | 26.2469 | 25.5507 | 25.4039 | 24.8208 |
Diluted EPS Excluding Extraordinary Items | -0.14553 | -0.1596 | -0.16035 | -0.05338 | -0.21865 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.15495 | -0.15259 | -0.13465 | -0.05389 | -0.21865 |
Unusual Expense (Income) | -0.411 | 0.283 | 1.01 | -0.02 | |
Cost of Revenue, Total | 3.232 | 2.722 | 0.451 | 0.366 | 0.411 |
Gross Profit | 3.743 | 4.322 | 13.173 | 7.622 | 6.79 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 46.318 | 25.758 | 50.077 | 78.348 | 28.058 |
Cash and Short Term Investments | 5.311 | 5.473 | 44.923 | 0.107 | 14.612 |
Cash & Equivalents | 5.311 | 5.473 | 44.923 | 0.107 | 14.612 |
Total Receivables, Net | 38.871 | 18.478 | 3.254 | 2.035 | 10.267 |
Accounts Receivable - Trade, Net | 36.183 | 15.245 | 3.085 | 1.831 | 3.226 |
Total Inventory | 0.12 | 0.118 | 0.185 | 0.136 | 1.66 |
Prepaid Expenses | 0.958 | 1.188 | 1.07 | 0.382 | 1.132 |
Total Assets | 90.928 | 59.841 | 77.684 | 92.495 | 73.876 |
Property/Plant/Equipment, Total - Net | 25.138 | 11.286 | 4.547 | 3.03 | 12.458 |
Goodwill, Net | 8.187 | 8.403 | 8.745 | 4.812 | 15.266 |
Intangibles, Net | 9.694 | 11.821 | 13.023 | 3.348 | 16.642 |
Long Term Investments | 0.135 | 0.152 | 0.175 | ||
Other Long Term Assets, Total | 1.456 | 1.168 | 1.117 | 0.334 | 0.44 |
Total Current Liabilities | 15.91 | 15.365 | 16.285 | 42.434 | 17.161 |
Accounts Payable | 4.429 | 5.238 | 8.649 | 5.549 | 4.583 |
Accrued Expenses | 4.98 | 2.873 | 2.74 | 3.644 | 4.551 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 4.564 | 5.903 | 4.138 | 0.807 | 1.249 |
Other Current Liabilities, Total | 1.937 | 1.351 | 0.758 | 32.434 | 6.778 |
Total Liabilities | 63.367 | 21.353 | 25.105 | 87.018 | 47.771 |
Total Long Term Debt | 13.438 | 4.895 | 7.264 | 12.143 | 3.508 |
Long Term Debt | 13.343 | 4.854 | 7.2 | 12.143 | 2.847 |
Deferred Income Tax | 0.058 | 1.656 | |||
Minority Interest | 31.713 | 0.143 | 0.149 | 31.556 | 24.869 |
Other Liabilities, Total | 2.306 | 0.95 | 1.407 | 0.827 | 0.577 |
Total Equity | 27.561 | 38.488 | 52.579 | 5.477 | 26.105 |
Common Stock | 0.003 | 0.003 | 0.003 | 0.002 | 0.002 |
Additional Paid-In Capital | 150.355 | 145.916 | 140.397 | 94.691 | 90.597 |
Retained Earnings (Accumulated Deficit) | -121.261 | -106.372 | -88.319 | -89.429 | -65.163 |
Other Equity, Total | -0.27 | 0.207 | 0.748 | 0.213 | 0.669 |
Total Liabilities & Shareholders’ Equity | 90.928 | 59.841 | 77.684 | 92.495 | 73.876 |
Total Common Shares Outstanding | 25.5458 | 24.3361 | 24.1678 | 16.141 | 15.5403 |
Other Current Assets, Total | 1.058 | 0.501 | 0.645 | 75.688 | 0.387 |
Note Receivable - Long Term | 1.253 | 2.623 | 1.012 | ||
Capital Lease Obligations | 0.095 | 0.041 | 0.064 | 0.661 | |
Property/Plant/Equipment, Total - Gross | 29.09 | 14.226 | 6.736 | 4.468 | |
Accumulated Depreciation, Total | -3.952 | -2.94 | -2.189 | -1.438 | |
Treasury Stock - Common | -1.266 | -1.266 | -0.25 | 0 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 49.45 | 46.318 | 31.856 | 25.458 | 24.01 |
Cash and Short Term Investments | 2.674 | 5.311 | 3.015 | 2.303 | 1.123 |
Cash & Equivalents | 2.674 | 5.311 | 3.015 | 2.303 | 1.123 |
Total Receivables, Net | 40.464 | 38.871 | 26.395 | 21.798 | 20.846 |
Accounts Receivable - Trade, Net | 37.739 | 36.183 | 23.744 | 18.786 | 17.075 |
Total Inventory | 0.128 | 0.12 | 0.095 | 0.107 | 0.113 |
Prepaid Expenses | 5.127 | 0.958 | 0.899 | 0.793 | 1.438 |
Other Current Assets, Total | 1.057 | 1.058 | 1.452 | 0.457 | 0.49 |
Total Assets | 93.267 | 90.928 | 70.69 | 62.799 | 58.538 |
Property/Plant/Equipment, Total - Net | 24.712 | 25.138 | 17.566 | 15.145 | 11.99 |
Goodwill, Net | 8.069 | 8.187 | 7.764 | 8.174 | 8.329 |
Intangibles, Net | 9.43 | 9.694 | 10.72 | 11.207 | 11.539 |
Long Term Investments | 0.136 | 0.135 | 1.739 | 1.75 | 1.574 |
Other Long Term Assets, Total | 1.47 | 1.456 | 1.045 | 1.065 | 1.096 |
Total Current Liabilities | 13.938 | 15.91 | 34.168 | 16.245 | 15.253 |
Accounts Payable | 4.387 | 4.429 | 4.538 | 5.203 | 6.933 |
Accrued Expenses | 5.041 | 4.98 | 5.627 | 4.16 | 3.568 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 2.376 | 4.564 | 22.504 | 5.585 | 3.375 |
Other Current Liabilities, Total | 2.134 | 1.937 | 1.499 | 1.297 | 1.377 |
Total Liabilities | 65.6 | 63.367 | 40.478 | 31.046 | 23.836 |
Total Long Term Debt | 17.369 | 13.438 | 5.186 | 13.972 | 7.58 |
Long Term Debt | 17.29 | 13.343 | 5.162 | 13.943 | 7.544 |
Capital Lease Obligations | 0.079 | 0.095 | 0.024 | 0.029 | 0.036 |
Minority Interest | 31.641 | 31.713 | 0.038 | 0.09 | 0.155 |
Other Liabilities, Total | 2.652 | 2.306 | 1.086 | 0.739 | 0.848 |
Total Equity | 27.667 | 27.561 | 30.212 | 31.753 | 34.702 |
Common Stock | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 |
Additional Paid-In Capital | 154.691 | 150.355 | 149.465 | 149.094 | 146.29 |
Retained Earnings (Accumulated Deficit) | -125.45 | -121.261 | -117.164 | -115.808 | -110.381 |
Treasury Stock - Common | -1.266 | -1.266 | -1.266 | -1.266 | -1.266 |
Other Equity, Total | -0.311 | -0.27 | -0.826 | -0.27 | 0.056 |
Total Liabilities & Shareholders’ Equity | 93.267 | 90.928 | 70.69 | 62.799 | 58.538 |
Total Common Shares Outstanding | 27.8615 | 25.5458 | 25.5458 | 24.8208 | 24.8208 |
Note Receivable - Long Term | 0 | 0 | 0 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -12.169 | -18.059 | 0.579 | -26.041 | -2.907 |
Cash From Operating Activities | -24.924 | -26.866 | -78.046 | -13.22 | -1.077 |
Cash From Operating Activities | 1.978 | 1.864 | 1.435 | 3.806 | 0.265 |
Deferred Taxes | -0.103 | 0 | -1.378 | 0.304 | -0.058 |
Non-Cash Items | 5.246 | 4.726 | -76.784 | 5.717 | 0.746 |
Changes in Working Capital | -19.876 | -15.397 | -1.898 | 2.994 | 0.877 |
Cash From Investing Activities | -14.133 | -12.384 | 105.61 | -13.778 | -0.592 |
Capital Expenditures | -12.416 | -7.866 | -1.525 | -12.129 | -0.535 |
Other Investing Cash Flow Items, Total | -1.717 | -4.518 | 107.135 | -1.649 | -0.057 |
Cash From Financing Activities | 39.578 | -0.106 | 5.881 | 24.098 | 0.197 |
Financing Cash Flow Items | 20.593 | 13.2 | 0 | ||
Issuance (Retirement) of Stock, Net | 2.181 | 0.91 | 8.488 | 0 | |
Issuance (Retirement) of Debt, Net | 16.804 | -1.016 | -2.607 | 10.898 | 0.197 |
Foreign Exchange Effects | -0.126 | -0.238 | 0.082 | -0.058 | 0.015 |
Net Change in Cash | 0.395 | -39.594 | 33.527 | -2.958 | -1.457 |
Cash Taxes Paid | 0 | 0.156 | |||
Cash Interest Paid | 0.458 | 0 | 0.157 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -4.261 | -12.169 | -10.897 | -9.489 | -3.997 |
Cash From Operating Activities | -7.24 | -24.924 | -14.163 | -9.206 | -2.792 |
Cash From Operating Activities | 0.578 | 1.978 | 1.463 | 0.975 | 0.474 |
Deferred Taxes | 0.003 | -0.103 | |||
Non-Cash Items | 0.277 | 5.246 | 2.937 | 2.014 | 0.963 |
Changes in Working Capital | -3.837 | -19.876 | -7.666 | -2.706 | -0.232 |
Cash From Investing Activities | -1.307 | -14.133 | -7.458 | -4.863 | -1.613 |
Capital Expenditures | -1.285 | -12.416 | -6.971 | -4.352 | -0.902 |
Other Investing Cash Flow Items, Total | -0.022 | -1.717 | -0.487 | -0.511 | -0.711 |
Cash From Financing Activities | 5.91 | 39.578 | 20.095 | 10.906 | 0.001 |
Financing Cash Flow Items | 20.593 | 1.084 | 0 | ||
Issuance (Retirement) of Stock, Net | 3.441 | 2.181 | 2.181 | 2.181 | 0.006 |
Issuance (Retirement) of Debt, Net | 2.469 | 16.804 | 16.83 | 8.725 | -0.005 |
Foreign Exchange Effects | -0.001 | -0.126 | 0.019 | -0.051 | 0.043 |
Net Change in Cash | -2.638 | 0.395 | -1.507 | -3.214 | -4.361 |
Cash Interest Paid | 0.785 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Orgenesis Inc. Company profile
About Orgenesis Inc
Orgenesis Inc. is a biotech company operating to unlock the potential of cell and gene therapies (CGTs). The Company is focused on autologous (using the patient’s own cells) therapies with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment. The Company has developed a Point of Care Platform comprised of three components: POCare Therapies, POCare Technologies and POCare Network. Its therapeutic portfolio pipeline is diverse and addresses various clinical needs. POCare Technology uses automated systems across a collaborative POCare Network via a combination of science, technology, engineering and networking.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Orgenesis Inc revenues increased from $5.4M to $28.6M. Net loss before extraordinary items decreased 70% to $13M. Revenues reflect POC Services segment increase from $4.3M to $17.1M, Cell process development services segment increase from $1.1M to $11.5M. Lower net loss reflects Other research and development expenses decrease of 43% to $5.6M (expense).
Equity composition
Common Stock $.001 Par, 4/13, 1.75B auth., 49,617,903 issd. Insider owns approx.50.56% Effective August 31, 2011 effected a 35 to one forward stock split
Industry: | Medical Equipment, Supplies & Distribution (NEC) |
20271 Goldenrod Lane
GERMANTOWN
MARYLAND 20876
US
Income Statement
- Annual
- Quarterly
News

How to Trade The Triple Top
Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.
14:13, 27 September 2023
Q4 lookahead: US indices starting to show signs of trouble?
US indices start to draw attention as traders focus on the outlook for Q4.
07:20, 27 September 2023
USD/JPY Climbs Towards Key Highs
USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.
11:32, 26 September 2023
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com